

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 37/02, C07K 7/64</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 90/06763</b> <b>(43) International Publication Date:</b> 28 June 1990 (28.06.90)
<b>(21) International Application Number:</b> PCT/US89/05484 <b>(22) International Filing Date:</b> 5 December 1989 (05.12.89) <b>(30) Priority data:</b> 280,009 5 December 1988 (05.12.88) US <b>(71) Applicant:</b> THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; Broadway and West 116th Street, New York, NY 10027 (US). <b>(72) Inventors:</b> ERLANGER, Bernard, F. ; 163-16 15 Drive, Whitestone, NY 11357 (US). CLEVELAND, William, L. ; 605 W. 113th Street, No. 23, New York, NY 10025 (US). CACALANO, Nicholas, A. ; 15 South Buckhout Street, Irvington, NY 10533 (US).		<b>(74) Agent:</b> WHITE, John, P.; Cooper & Dunham, 30 Rockefeller Plaza, New York, NY 10112 (US). <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> NOVEL DERIVATIVES OF CYCLOSPORINE A, ANTIBODIES DIRECTED THERETO AND USES THERE-OF  <b>(57) Abstract</b> <p>This invention provides a molecule comprising cyclosporine A or a congener of cyclosporine A which is photochemically attached to a ligand containing a reactive group. This invention also provides a composition of matter which comprises a conjugate of a compound and the aforementioned molecule wherein the compound is bound to the molecule through the reactive group. This invention further provides an antibody directed to the aforementioned composition of matter specific for cyclosporine A or congener of cyclosporine A. Finally, this invention provides a method of monitoring levels of cyclosporine A or congener of cyclosporine A in a subject.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

-1-

NOVEL DERIVATIVES OF CYCLOSPORINE A, ANTIBODIES DIRECTED THERETO AND USES THEREOF

5 This invention was made with government support under Grant Numbers RO1 NS-15581 and PO1 HL-36581 and training grants 2-T32-AI-07161-11 and T32-CA-09503 from the National Institute of Health, U.S. Department of Health and Human Resources. Accordingly, the U.S. Government has certain rights in the invention.

10 Background of the Invention

15 Throughout this application, various publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed in this application.

20 Cyclosporine A (CsA) is a cyclic undecapeptide of fungal origin which is an immunosuppressive agent useful in preventing organ rejection in transplant patients (1-3).

25 Because the therapeutic index of CsA is narrow, it is important to measure serum cyclosporine levels in patients treated with CsA (4). This can be accomplished by high performance liquid chromatography or by RIA, with the latter procedure being the more convenient one.

30

35

-2-

5 It has been reported, and we have confirmed (unpublished), that CsA, itself, is non-immunogenic (5). To obtain antibodies, therefore, it is necessary to link CsA to a protein carrier. The side chains of CsA, however, consist only of aliphatic groups with none of the functional groups customarily used to link a hapten to a carrier. Previous workers have made immunogenic cyclosporine C (CsC)-protein conjugates because CsC has a threonine residue in position 2 (5). Linkage to a protein was via a hemisuccinate, using a water soluble carbodiimide as a coupling agent. Polyclonal antisera were successfully raised in this way and are routinely used to measure CsA in patients sera (5). More recently, monoclonal antibodies were prepared using an activated ester of a lysyl-CsA derivative (6).

20 We have chosen to use CsA, itself, as a hapten by converting it to a reactive carboxyl-containing peptide via a photochemical reaction. Coupling of this derivative to proteins has led to the successful raising of CsA-specific rabbit antibodies that can be used to measure CsA levels in sera of transplant patients under treatment with CsA.

25


30

35

-3-

Summary of the Invention

The present invention provides a molecule having the structure:






wherein each R may independently be H or X, provided that at least one R is X, where X is a ligand which is produced as the result of a photochemical reaction between a precursor of X containing a photochemically activatable group and a hydrogen of cyclosporine A and which comprises a reactive group.

The invention further provides that the reactive group may be a group which is reactive with a macromolecule. In a preferred embodiment of this invention, the macromolecule may be a polypeptide. In a very preferred embodiment, the invention further provides that the polypeptide may be a protein. In a preferred embodiment, the reactive group may be a carboxyl.


35

-4-

Specific examples of X may include but are not limited to the following:



and



In a preferred embodiment of the invention, the probability is greater than 0.75 that only one R in the aforementioned molecule is X. In a very preferred embodiment, the probability is about 1.0.

The present invention further provides a molecule which comprises a congener of cyclosporine A characterized by the structural backbone of cyclosporine A in which one

-5-

5 or more hydrogen atoms are replaced by one or more ligands, each such ligand both comprising a reactive group and being attached to the structural backbone of cyclosporine A at a location which a hydrogen atom has been replaced as the result of a photochemical reaction between a precursor of the ligand containing a photochemically activatable group and the hydrogen atom being replaced.

10 The present invention further provides an immunosuppressive agent useful for preventing organ rejection in a transplant subject comprising an amount of the aforementioned molecules effective to inhibit organ rejection in a transplant subject and a pharmaceutically acceptable carrier.

15 The present invention also provides a composition of matter which comprises a conjugate of a compound and the aforementioned molecule wherein the compound is bound to the molecule through the reactive group of the ligand X.

20 The invention further provides a composition of matter which comprises a conjugate of a macromolecule and the aforementioned molecule wherein the macromolecule is bound to the molecule through the reactive group of the ligand X.

25 Similarly, the invention provides a composition of matter which comprises a conjugate of a polypeptide and the aforementioned molecule wherein the polypeptide is bound to the molecule through the reactive group of the ligand X.

35

-6-

Moreover, the invention provides a composition of matter which comprises a conjugate of a protein and the aforementioned molecule wherein the protein is bound to the molecule through the reactive group of the ligand X. Specific examples of this protein includes bovine serum albumin, rabbit serum albumin, keyhole limpet hemocyanin, ovalbumin, or any globulin including but not limited to thyroglobulin.

The invention also provides a method for preventing rejection in a transplant subject comprising administering to the subject an amount of the aforementioned molecule effective to inhibit organ rejection in the transplant subject.

The subject invention further provides an antibody directed to the aforementioned composition of matter specific for cyclosporine A or congener of cyclosporine A. In accordance with the teachings of the invention, the antibody may further be characterized as polyclonal or monoclonal. These antibodies may be detectably labeled.

The invention further provides a method of detecting the presence of cyclosporine A or congener of cyclosporine A in a biological tissue sample which comprises treating the biological tissue sample with the aforementioned detectably labeled antibody under conditions permitting the antibody to bind to cyclosporine A or congener and form a complex therewith, removing labeled antibody which is not bound to cyclosporine A or congener, detecting the presence of labeled antibody bound to cyclosporine A or congener and thereby detecting the presence of cyclosporine A or congener in the biological tissue sample.



-7-

5 The invention further provides another method of detecting the presence of cyclosporine A or a congener of cyclosporine A in a biological tissue sample which comprises treating the biological tissue sample with the aforementioned unlabeled antibody under conditions permitting the antibody to bind to cyclosporine A or congener and form a complex therewith, removing antibody which is not bound to cyclosporine A or congener, 10 treating the complex with a labeled antibody directed to the unlabeled antibody under conditions such that the labeled antibody binds to the unlabeled antibody of the complex, removing labeled antibody which is not bound to the complex, detecting the presence of labeled antibody bound to the complex and thereby detecting the 15 presence of cyclosporine A or congener in the biological tissue sample.

20 Additionally, this invention provides a method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample which comprises, contacting a solid support with an excess of the aforementioned composition of matter under conditions permitting the composition of matter to attach to the surface of the solid support, 25 contacting a predetermined volume of biological fluid sample with a predetermined amount of the aforementioned labeled antibody under conditions such that the cyclosporine A or congener in the sample binds to the labeled antibody and forms a complex therewith, contacting the 30 resulting complex to the solid support to the surface of which the composition of matter is attached under conditions permitting the labeled antibody of the complex to bind to the composition of matter, treating the solid support so that only the composition of matter 35

-8-

5 and labeled antibody of the complex bound thereto remain, quantitatively determining the amount of labeled antibody of the complex bound to the composition of matter, and thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.

10 This invention provides another method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample which comprises contacting a solid support with an excess of the  
15 aforementioned composition of matter under conditions permitting the composition of matter to attach to the surface of the solid support, contacting a predetermined volume of biological fluid sample with a predetermined amount of the aforementioned antibody under  
20 conditions such that the cyclosporine A or congener in the sample binds to the antibody and forms a complex therewith, contacting this complex with a predetermined amount of labeled antibody directed to the unlabeled  
25 antibody under conditions such that the labeled antibody binds to the unlabeled antibody complex of the prior step and forms a labeled complex therewith, contacting the resulting labeled complex to the solid support to the surface of which the composition of matter  
30 is attached under conditions permitting the unlabeled antibody bound to the labeled antibody of the labeled complex to bind to the composition of matter, treating the solid support so that only the composition of matter and labeled complex bound thereto remain,  
35 quantitatively determining the amount of labeled antibody of the labeled complex bound to the unlabeled antibody which is in turn bound to the composition of matter, and thereby determining the concentration of cyclosporine A or congener in the biological fluid

-9-

sample.

5 In the two aforementioned methods of determining the concentration of cyclosporine A or congener, the composition of matter may be attached to the surface of the plate by covalent or noncovalent bonds.

10 The invention also provides a method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample by radioimmunoassay which comprises radioactively labeling a predetermined amount of a substance comprising cyclosporine A, congener of cyclosporine A or the aforementioned composition of matter, adding the predetermined amount of radiolabeled substance to the biological fluid sample, 15 contacting this mixture with a predetermined amount of the aforementioned unlabeled antibody under conditions suitable to permit the antibody to bind to the cyclosporine A or congener in the biological fluid sample and the labeled substance, removing any unbound radiolabeled substance, quantitatively determining the amount of 20 labeled substance bound to the antibody, and thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.

25 The invention also provides a method of monitoring levels of cyclosporine A or congener of cyclosporine A in a subject which comprises taking biological fluid samples from a subject at predetermined intervals and determining the amount of cyclosporine A or congener in 30 each biological fluid sample according to the aforementioned assays.

35 The aforementioned biological fluid may be, but is not limited to, blood, urine, feces or extracts of tissue.

-10-

5 The invention additionally provides a method for producing a monoclonal auto-anti-idiotypic antibody which comprises contacting lymphoid cells of an animal under suitable conditions with an effective antibody-raising amount of the aforementioned composition of matter, collecting the lymphoid cells at a suitable time after the contacting, fusing the collected lymphoid cells with appropriate myeloma cells to produce a series of hybridoma cells each of which produces a monoclonal antibody, screening under suitable conditions the series of hybridoma cells so produced to identify those which secrete a monoclonal antibody capable of binding to an antibody directed to the aforementioned composition of matter, separately culturing a hybridoma cell so identified in an appropriate medium, and separately recovering under suitable conditions the monoclonal anti-idiotypic antibody produced by the hybridoma cell.

20 The invention further provides an antibody directed to the aforementioned monoclonal auto-anti-idiotypic antibody. Additionally, the invention provides an antibody directed to the aforementioned antibodies. These antibodies directed to other antibodies may be used in an immunoregulatory substance useful for preventing organ rejection in a transplant subject in an amount effective to inhibit organ rejection in a transplant subject and a pharmaceutically acceptable carrier.

30 The invention further provides a method of reducing the amount of cyclosporine A or congener in a subject which comprises administering intravenously to the subject an amount of the aforementioned antibody effective to reduce the amount of cyclosporine A and permitting the antibody to bind to the excess cyclosporine A, thereby

35

-11-

rendering the excess cyclosporine A ineffective.

5 The invention also provides a method of reducing the amount of endogenous immunoregulatory substances, or other biologically active substances which are endogenous, which share epitopes with cyclosporine A or congener of cyclosporine A in a subject which comprises administering intravenously to the subject an amount of aforementioned antibody or fragment thereof effective to reduce the amount of endogenous substances and 10 permitting the antibody or fragment thereof to bind to the excess endogenous substances, thereby rendering the excess endogenous substances ineffective.

15 Finally, the invention provides a method of testing the potential of a pharmacological agent as an immunoactive agent which comprises running an immunochemical assay competitive between the pharmacological agent and known amounts of labeled cyclosporine A or congener of cyclosporine A with the aforementioned antibody under conditions such that the antibody forms complexes with the 20 pharmacological agent and cyclosporine A or congener and determining the displacement from the antibody of labeled cyclosporine A or congener by the pharmacological agent.

25

30

35

**Brief Description of the Figures**

Figure 1 shows the photochemical reaction between CsA and BBA.

5 Figure 2 shows the Scatchard plot of binding data.

Figure 3 shows the inhibition of the binding of CsA to R575 by various cyclosporine derivatives.

10 Figure 4 shows the titers (ng/ml) of patients' sera as determined by RIA using R575 and Sandoz antibody.

15

20


25

30

35

## Detailed Description of the Invention

The present invention provides a molecule having the structure:



wherein each R may independently be H or X, provided that at least one R is X, where X is a ligand which is produced as the result of a photochemical reaction between a precursor of X containing a photochemically activatable group and a hydrogen of cyclosporine A and which comprises a reactive group.



The invention further provides that the reactive group may be a group which is reactive with a macromolecule. Examples of such macromolecules include, but are not limited to, polysaccharides, complex carbohydrates, and any organic polymers including but not limited to polyacrilimide, polynitrocellulose, and polystyrene. In a preferred embodiment of this invention, the macro-

-14-

molecule may be a polypeptide. In a very preferred embodiment, the invention further provides that the polypeptide may be a protein.

5 In a further embodiment of the invention, the reactive group may be an ester, carbanyl, amine or phosphonamide. In a preferred embodiment, the reactive group may be a carboxyl.

10 Photochemical reactions are well known in the art (7) and it is to be understood that X may be any ligand which is produced as the result of a photochemical reaction between a precursor of X containing a photochemically activatable group and a hydrogen of cyclosporine A and which comprises a reactive group. Specific  
15 examples of X may include but are not limited to the following:




and

35



-15-



5

In a preferred embodiment of the invention, the probability is greater than 0.75 that only one R in the aforementioned molecule is X. In a very preferred embodiment, the probability is about 1.0.

10

The present invention further provides a molecule which comprises a congener of cyclosporine A characterized by the structural backbone of cyclosporine A in which one or more hydrogen atoms are replaced by one or more ligands, each such ligand both comprising a reactive group and being attached to the structural backbone of cyclosporine A at a location which a hydrogen atom has been replaced as the result of a photochemical reaction between a precursor of the ligand containing a photochemically activatable group and the hydrogen atom being replaced.


20

Congeners of cyclosporine A currently exist in the literature (5, 8) and it is anticipated that many more may be developed. It is foreseen that the novelties of the subject application which are applicable to cyclosporine A may also be applicable to such congeners. The basic structure of cyclosporine A is as follows:

30

35

-16-



15 Examples of such congeners include, but are not limited to, cyclosporine A with:

- 20
- (a) alanine at position 2;
  - (b) threonine at position 2;
  - (c) valine at position 2;
  - (d) norvaline at position 2 and 5; and
  - (e) alphaamino butyric acid at position 7.

25 The present invention further provides an immunosuppressive agent useful for preventing organ rejection in a transplant subject comprising an amount of the aforementioned molecules effective to inhibit organ rejection in a transplant subject and a pharmaceutically acceptable carrier.

30 As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers. Such carriers are well known in the art and may include, but are not intended to be limited to, any of the standard pharmaceutical carriers such as phos-

35

-17-

phate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents.

5 The aforementioned immunosuppressive compositions may be superior to cyclosporine A in several ways. First, the compositions may avoid the toxicity problems inherent with cyclosporine A, specifically kidney damage. Sec-  
10 ond, these compositions may be soluble and thereby preferable for dosage regulation.

15 The present invention also provides a composition of matter which comprises a conjugate of a compound and the aforementioned molecule wherein the compound is bound to the molecule through the reactive group of the  
ligand X. The general process for preparation of anti-  
genic hapten-carrier conjugates is known in the art  
(9).

20 The invention further provides a composition of matter which comprises a conjugate of a macromolecule and the aforementioned molecule wherein the macromolecule is bound to the molecule through the reactive group of the  
ligand X.

25 Similarly, the invention provides a composition of matter which comprises a conjugate of a polypeptide and the aforementioned molecule wherein the polypeptide is bound to the molecule through the reactive group of the  
ligand X.

30 Moreover, the invention provides a composition of matter which comprises a conjugate of a protein and the aforementioned molecule wherein the protein is bound to the molecule through the reactive group of the ligand  
35

-18-

5 X. Again, it is to be understood that the scope of the invention includes any protein capable of being bound to the molecule. Specific examples of this protein includes bovine serum albumin, rabbit serum albumin, keyhole limpet hemocyanin, ovalbumin, or any globulin including but not limited to thyroglobulin.

10 The invention also provides a method for preventing rejection in a transplant subject comprising administering to the subject an amount of the aforementioned molecule effective to inhibit organ rejection in the transplant subject.

15 The subject invention further provides an antibody directed to the aforementioned composition of matter specific for cyclosporine A or congener of cyclosporine A. In accordance with the teachings of the invention, the antibody may further be characterized as polyclonal or monoclonal.

20 These antibodies may be detectably labeled. Such labels are well known in the art and include but are not limited to enzyme labels and radioactive labels such as fluorophore or biotinylated labels.

25 The invention further provides a method of detecting the presence of cyclosporine A or congener of cyclosporine A in a biological tissue sample which comprises treating the biological tissue sample with the aforementioned detectably labeled antibody under conditions  
30 permitting the antibody to bind to cyclosporine A or congener and form a complex therewith, removing labeled antibody which is not bound to cyclosporine A or congener, detecting the presence of labeled antibody bound to cyclosporine A or congener and thereby detecting the  
35

-19-

presence of cyclosporine A or congener in the biological tissue sample.

5 The invention further provides another method of detecting the presence of cyclosporine A or a congener of cyclosporine A in a biological tissue sample which comprises treating the biological tissue sample with the aforementioned unlabeled antibody under conditions permitting the antibody to bind to cyclosporine A or congener and form a complex therewith, removing antibody which is not bound to cyclosporine A or congener, 10 treating the complex with a labeled antibody directed to the unlabeled antibody under conditions such that the labeled antibody binds to the unlabeled antibody of the complex, removing labeled antibody which is not bound to the complex, detecting the presence of labeled antibody bound to the complex and thereby detecting the presence of cyclosporine A or congener in the biological tissue sample. 15

20 Detecting the presence of cyclosporine A or congener in biological tissue sample is useful since the toxic effects of cyclosporine A include damage to tissues, particularly kidney. Accordingly, in a preferred embodiment of the method of detecting the presence of cyclosporine A or congener, the biological tissue sample is kidney. 25

30 Additionally, this invention provides a method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample which comprises, contacting a solid support with an excess of the aforementioned composition of matter under conditions permitting the composition of matter to attach to the surface of the solid support, contact- 35

-20-

5 ing a predetermined volume of biological fluid sample  
with a predetermined amount of the aforementioned la-  
beled antibody under conditions such that the cyclosp-  
orine A or congener in the sample binds to the labeled  
antibody and forms a complex therewith, contacting the  
10 resulting complex to the solid support to the surface  
of which the composition of matter is attached under  
conditions permitting the labeled antibody of the com-  
plex to bind to the composition of matter, treating the  
solid support so that only the composition of matter  
and labeled antibody of the complex bound thereto re-  
main, quantitatively determining the amount of labeled  
antibody of the complex bound to the composition of  
matter, and thereby determining the concentration of  
15 cyclosporine A or congener in the biological fluid sam-  
ple.

This invention provides another method of determining  
the concentration of cyclosporine A or congener of  
cyclosporine A in a biological fluid sample which com-  
20 prises contacting a solid support with an excess of the  
aforementioned composition of matter under conditions  
permitting the composition of matter to attach to the  
surface of the solid support, contacting a predeter-  
mined volume of biological fluid sample with a prede-  
25 termined amount of the aforementioned antibody under  
conditions such that the cyclosporine A or congener in  
the sample binds to the antibody and forms a complex  
therewith, contacting this complex with a predetermined  
amount of labeled antibody directed to the unlabeled  
30 antibody under conditions such that the labeled anti-  
body binds to the unlabeled antibody complex of the  
prior step and forms a labeled complex therewith, con-  
tacting the resulting labeled complex to the solid  
support to the surface of which the composition of mat-  
35

-21-

ter is attached under conditions permitting the unlabeled antibody bound to the labeled antibody of the labeled complex to bind to the composition of matter, treating the solid support so that only the composition of matter and labeled complex bound thereto remain, quantitatively determining the amount of labeled antibody of the labeled complex bound to the unlabeled antibody which is in turn bound to the composition of matter, and thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.

In the two aforementioned methods of determining the concentration of cyclosporine A or congener, the composition of matter may be attached to the surface of the plate by covalent or noncovalent bonds.

The invention also provides a method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample by radioimmunoassay which comprises radioactively labeling a predetermined amount of a substance comprising cyclosporine A, congener of cyclosporine A or the aforementioned composition of matter, adding the predetermined amount of radiolabeled substance to the biological fluid sample, contacting this mixture with a predetermined amount of the aforementioned unlabeled antibody under conditions suitable to permit the antibody to bind to the cyclosporine A or congener in the biological fluid sample and the labeled substance, removing any unbound radiolabeled substance, quantitatively determining the amount of labeled substance bound to the antibody, and thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.

-22-

5       Methods of determining the concentration of cyclosporine A or congener in the biological fluid sample from data concerning labeled complex is well known in the art. One such example includes comparing the data to a standard curve.

10       It is to be understood that it is within the scope of the present invention to use other types of assays with the aforementioned antibodies for determining the concentration of cyclosporine A in a biological fluid sample.

15       The invention also provides a method of monitoring levels of cyclosporine A or congener of cyclosporine A in a subject which comprises taking biological fluid samples from a subject at predetermined intervals and determining the amount of cyclosporine A or congener in each biological fluid sample according to the aforementioned assays.

20       The aforementioned biological fluid may be, but is not limited to, blood, urine, feces or extracts of tissue.

25       The invention additionally provides a method for producing a monoclonal auto-anti-idiotypic antibody which comprises contacting lymphoid cells of an animal under suitable conditions with an effective antibody-raising amount of the aforementioned composition of matter, collecting the lymphoid cells at a suitable time after  
30       the contacting, fusing the collected lymphoid cells with appropriate myeloma cells to produce a series of hybridoma cells each of which produces a monoclonal antibody, screening under suitable conditions the series of hybridoma cells so produced to identify those  
35



-23-

which secrete a monoclonal antibody capable of binding to an antibody directed to the aforementioned composition of matter, separately culturing a hybridoma cell so identified in an appropriate medium, and separately recovering under suitable conditions the monoclonal anti-idiotypic antibody produced by the hybridoma cell. Methods of producing monoclonal auto-anti-idiotypic antibodies are previously known in the art as outlined in co-pending patent application U.S. Serial No. , filed November 18, 1988, continuation of U.S. Serial No. 767,56, filed August 20, 1985.

The invention further provides an antibody directed to the aforementioned monoclonal auto-anti-idiotypic antibody. Additionally, the invention provides an antibody directed to the aforementioned antibodies. These antibodies directed to other antibodies may be used in an immunoregulatory substance useful for preventing organ rejection in a transplant subject in an amount effective to inhibit organ rejection in a transplant subject and a pharmaceutically acceptable carrier.

The invention further provides a method of reducing the amount of cyclosporine A or congener in a subject which comprises administering intravenously to the subject an amount of the aforementioned antibody effective to reduce the amount of cyclosporine A and permitting the antibody to bind to the excess cyclosporine A, thereby rendering the excess cyclosporine A ineffective.

The invention also provides a method of reducing the amount of endogenous immunoregulatory substances, or other biologically active substances which are endogenous, which share epitopes with cyclosporine A or congener of cyclosporine A in a subject which comprises

-24-

5 administering intravenously to the subject an amount of aforementioned antibody or fragment thereof effective to reduce the amount of endogenous substances and permitting the antibody or fragment thereof to bind to the excess endogenous substances, thereby rendering the excess endogenous substances ineffective.

10 Finally, the invention provides a method of testing the potential of a pharmacological agent as an immunoactive agent which comprises running an immunochemical assay competitive between the pharmacological agent and known amounts of labeled cyclosporine A or congener of cyclosporine A with the aforementioned antibody under conditions such that the antibody forms complexes with the pharmacological agent and cyclosporine A or congener and determining the displacement from the antibody of labeled cyclosporine A or congener by the pharmacological agent.

20 This invention is illustrated in the Experimental Details section which follows. This section is set forth to and in an understanding of the invention but is not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.

25

30

35

-25-

Experimental Details

## EXAMPLE I

Materials and Methods

5

10

15

4-Benzoylbenzoic acid (BBa) was purchased from Aldrich Chemicals. Bovine and rabbit serum albumin (BSA and RSA) and N-hydroxysuccinimide were from Sigma Chemical. Dicyclohexylcarbodiimide was from Fluka. Cyclosporin A (CsA), [<sup>3</sup>H]CsA (50Ci/mMole), Cyclosporin "RIA-kits" and the various modified derivatives were generous gifts from Sandoz Ltd., Basel, Switerland. [<sup>3</sup>H]CsA (17Ci/mMole) was purchased from Amersham. Kieselgel (silica gel 60 F254) was purchased from E. Merck (cat. no. 5766).

Photolysis reaction

20

25

30

35

CsA (104 mg, 83  $\mu$ moles) was mixed with 36 mg (160  $\mu$ moles) of BBa in 0.6 ml of benzene. The solution was purged with nitrogen gas and photolysed at 320nm with a Spectroline B100 UV lamp (Spectronics, Westbury, L.I.) for 7 hours at a distance of 8 cm, at room temperature. Approximately 1 microcurie of [<sup>3</sup>H] dihydro CsA was added as a tracer prior to exposure to UV. After photolysis, the benzene was evaporated in a rotating still in vacuo and the dried product dissolved in 1.5 ml of methanol. The product was isolated by preparative thin layer chromatography on silica gel, in a solvent system of CHCl<sub>3</sub>/methanol (85/15). Two major bands were seen: Rf = 0.58 and 0.72. The slower moving band (i.e. the product of the reaction, CsA-BBa) was eluted with methanol, and counted for radioactivity.

### Hapten-Protein Conjugates

5 CsA-BBa (5.5 mg, ca. 4  $\mu$ moles) was added to 1 ml solution containing 552  $\mu$ g (4.8  $\mu$ moles) of N-hydroxysuccinimide (NHS) and 825  $\mu$ g (4  $\mu$ moles) of dicyclohexylcarbodiimide in 1 ml of methanol. The reaction was allowed to run overnight at room temperature and ester formation was detected with a neutral Fe-hydroxamate test (10-11).

10 Carrier proteins (BSA or RSA) (10 mg; 0.14  $\mu$ mole) were dissolved in 1.0 ml of distilled H<sub>2</sub>O, and the pH adjusted to 9.0 with M Na<sub>2</sub>CO<sub>3</sub>. CsA-BBa-NHS (5.2mg; 3.6  $\mu$ moles) in 1.0 ml of methanol was added dropwise to the protein solution. After all was added, the pH was readjusted to 9 and the reaction allowed to proceed overnight at room temperature. The reaction mixture was then dialyzed against PBS for 24 hours and counted for radioactivity to determine coupling efficiency. 15 About 6-7 cyclosporins were coupled to each molecule of BSA or RSA. The conjugates were further purified by gel filtration HPLC (LKB TSK 3000). Confirmation of the linkage of CsA to the proteins came from RIA inhibition experiments. Quantitation is not possible by 20 this technique because there was no way to determine the valence of the conjugate as a competitive inhibitor, i.e., how many of the haptens linked to the protein took part in the inhibition reaction.

### Immunization

25 Two female New Zealand White rabbits were immunized intradermally along with the back, with a 1:1 (v:v) mixture of CsA-BBa-BSA in complete Freund's adjuvant (1 35

-27-

5 mg/ml of antigen). The rabbits were boosted with CsA-BBa-BSA in incomplete Freund's adjuvant at 3-4 week intervals and bled weekly following each boost. Both rabbits responded by producing cyclosporine-specific antibodies. The sera of one rabbit, R575, was characterized further.

#### Radioimmunoassay

10 Serum antibodies were detected by a modification of the published radioimmunoassay (5, 12). Serum (100  $\mu$ l) diluted in Sandoz buffer A (50 mM Tris, pH 8.5) was added to 200  $\mu$ l of [ $^3$ H]CsA in Sandoz buffer B (50 mM Tris, pH 8.5; 0.1% Tween 20) containing 2% horse serum, and incubated for 2 hours at room temperature or over-  
15 night at 4°C. Binding by diluted preimmune serum was used as a control. Free and bound ligand were separated with charcoal supplied by Sandoz according to their procedure.

#### 20 Determination of antibody specificity

Antibody specificity was determined by an inhibition RIA, using a panel of six CsA analogues, modified at different amino acid positions. The cyclosporin derivatives were dissolved in 100% ethanol at a concentration of 5.0 mg/ml, stored at -20°C, and diluted to  
25 final concentrations of .27 nM to 2.7  $\mu$ M in Sandoz buffer B for the inhibition experiments. A constant dilution of rabbit antibody, in buffer A, was added to  
30 200  $\mu$ l of buffer B containing [ $^3$ H] dihydro CsA and different amounts of inhibitor, and incubated overnight at 4°C. Inhibition curves for each CsA derivative were generated.

35

-28-

Detection of CsA in sera of transplant patients

5 Cyclosporin levels in the sera of 25 transplant patients were determined by an inhibition RIA, using either our rabbit anticyclosporin antibodies diluted 1:600 or a polyclonal antibody preparation supplied by Sandoz, as part of their kit. Diluted rabbit anti-cyclosporin antiserum (100  $\mu$ l) or Sandoz polyclonal antibody were added to 100  $\mu$ l [ $^3$ H]CsA in buffer B and 100  $\mu$ l of patient's serum prediluted either 1:5 (for Sandoz antibody) or 1:15 (for our rabbit antibody) in 10 buffer B, containing 2% horse serum. Sera from three different patients, taken before they had begun cyclosporin treatment, were used as controls. Samples were 15 incubated overnight at 4°C, and CsA levels were calculated by comparing the level of inhibition to a standard curve obtained with known amounts of cyclosporin.

Scatchard Analysis

20 The binding constant of the rabbit antibodies was determined by Scatchard analysis. Different concentrations of [ $^3$ H] dihydro CsA, ranging from 10nM to 0.1nM, were added to a constant amount of antibody and allowed to incubate overnight at 4°C, bound ligand was determined by the RIA described above. 25

Results

30 CsA lacks chemically active groups that can be used for conjugation to proteins. Therefore, a novel procedure was developed for the purpose of introducing carboxyl groups into the molecule. This procedure, photochemical in nature, inserts a carboxyl-containing molecule (BBa) into the alkyl side chains of CsA (Fig. 1), pre- 35

-29-

sumably but not certainly, at random.

5 Antibodies generated in rabbits with the CsA-BBa-BSA conjugate were examined for specificity and affinity by RIA. Scatchard analysis (Fig. 2) revealed a relatively homogenous population of high affinity antibodies, with  $K_d = 9.8 \pm 2.8 \times 10^{-11} M$ .

10 The specificity of the antibodies for various cyclosporin derivatives was determined by an inhibition RIA. The results are shown in Fig. 3 and Table I. The derivatives can be divided roughly into three groups according to their affinities: CsA, CsD, 665, 243 and 032 are in the high affinity group. CsC, 582 and 039 are of moderate affinities; 717 inhibits very poorly.

15 Shown in Table II are the results of assays of cyclosporin levels in the sera of patients undergoing CsA treatment subsequent to cardiac transplantation. Titters were determined using our antibodies and the polyclonal antibodies in the Sandoz kit. Also tabulated in Table II are data supplied by the laboratory of the Department of Surgery. As illustrated in Fig. 4, in our hands the levels determined with our antibody agreed with results using the commercial kit. Linear regression analysis of the data yields a slope of 0.88 and a correlation coefficient of 0.84.

### Discussion

30 The  $\alpha$ ,  $\beta$  unsaturated ketone, BBa, is among reagents that, upon photoactivation by U.V. light, can insert into alphatic side chains (7). It was selected for this study because its photoactive intermediate does not cleave peptide bonds (13). This is an important

35

-30-

Table 1IC<sub>50</sub><sup>a</sup> of Various Analogues of CsA

5	Derivative <sup>b</sup>	IC <sub>50</sub> (nM)
	-----	-----
10	CsD	4.3
	665	4.8
	A	6.0
	243	6.0
	032	7.0
15	CsC	11.5
	582	12.0
	039	18.0
	717	2700

a IC<sub>50</sub> = Concentration for 50% inhibition

b The derivatives listed differ from CsA in the following ways: CsD, valine replaces  $\alpha$ -aminobutyric acid at position 2; 665, O-acetylthreonine replaces  $\alpha$ -aminobutyric acid at position 2; 243, hydroxyl group of (4R)-4-[(E)-2-butenyl]-4-N-dimethyl-L-threonine in position 1 is acetylated; 032, N-methylisoleucine replaces N-methylvaline at position 11; CsC, threonine replaces  $\alpha$ -aminobutyric acid at position 2; 582, proline replaces sarcosine at position 3; 039, N-methyl-D-alanine N-methylleucine at position 6; 717, O-t-butyl-D-serine replaces D-alanine at position 8.



-31-

Table 2

## Cyclosporine Titers in Patients' Sera (ng/ml)

	<u>Patient #</u>	<u>R575</u> <sup>a</sup>	<u>Commercial</u> <sup>b</sup>	<u>Hospital Laboratory</u> <sup>c</sup>
5				
	1	51	undetectable	30
10	2	190	170	128
	3	195	180	156
	4	135	120	76
	5	175	180	180
	6	135	110	88
	7	195	195	164
	8	205	185	172
	9	240	225	245
15	10	210	210	215
	11	113	125	180
	12	95	100	124
	13	77	113	124
	14	98	105	88
	15	84	100	112
	16	124	163	152
20	17	165	250	205
	18	135	190	180
	19	141	158	132
	20	231	250	188
	21	126	153	134
	22	81	113	88
	23	117	145	110
	24	107	175	148
25	25	57	60	71

<sup>a</sup> Antibody prepared according to details of this paper.

30 <sup>b</sup> Antibody in kit from Sandoz Ltd. Assay run in our laboratory.

<sup>c</sup> Results reported by hospital laboratory using Sandoz kit.

-32-

consideration because it has been shown that a single break in a peptide bond of CsA, such as in iso-CsA, which has lost a peptide bond by an N O shift, leads to loss of activity even though, in the case of Iso-CsA, a cyclic structure is maintained. Apparently an altered conformation leads to a biologically inactive molecule.

The insertion of BBa into CsA is probably a somewhat random process, although we have not attempted to characterize the various products. If random, we are generating populations of antibodies that recognize different residues of the CsA molecule. We have tried to learn something about these antibodies by doing inhibition studies with a panel of cyclosporin derivatives (Fig. 3, Table I). First of all, the relatively shallow slopes of the curves indicate that the immune response is oligo or polyclonal, probably the former. If it were monoclonal 90% inhibition would occur at a ten-fold higher concentration than 10% inhibition. A second important observation is that 100% inhibition of [<sup>3</sup>H] CsA binding can be obtained with all of the competing cyclosporin derivatives except 717, which, however, is certainly capable of more than 50% inhibition. These results indicate that all of the cyclosporin derivatives compete for the total population of antibodies specific for CsA.

The inhibition data in Table I and Fig. 3 indicate that the various cyclosporine derivatives can be divided into three groups with respect to their affinities for the population of antibodies in the immune sera. CsA, CsD, 665, 243 and 032 bind best. Moderate affinities are shown by CsC, 582 and 039. The results with 717 indicate low affinity. Derivative 717 differs from CsA by having a bulky O-t-butyl-D-serine instead of D-

-33-

alanine at position 8. This could implicate position 8 as a dominant epitope. On the other hand, introduction of a bulky group at position 8, in place of the compact methyl group of D-alanine, could distort the cyclosporine molecule markedly (6).

5

The derivatives showing moderate affinities, CsC, 582 and 039, are substituted at position 2, 3 and 6 respectively. None of the substitutions are bulky. However, the substitution of proline for sarcosine at position 3 is known to disturb the conformation of 582 at positions 3 and 4 (14).

10

Those derivatives having affinities similar to that of CsA are substituted in positions 1, 2 and 11, all clustered at one "face" of the cyclic peptide. The substitutions, however, are not drastic with respect to size differences of the side chains. A definitive study of the specificity of the antisera and correlation with conformation and biological activity requires testing with a larger number of cyclosporin analogues, which are available (14).

15

20

Assay of cyclosporin levels in patients' sera is feasible with this antibody preparation. Our results (Fig. 4 and Table II) are in good agreement with cyclosporin levels determined using commercial (Sandoz) antisera prepared by immunization with a protein conjugate of CsC. The moderate discrepancies probably indicate differences in cross specificities of the antibodies for metabolites of cyclosporine, (5), which is to be expected since our antigen differs from the antigen used to produce the commercial antiserum.

25

30

#### EXAMPLE II

35


Preparation of CyA-BSA Conjugate and CyA-Sepharose Affinity Column

5 The character of the side chains of CyA (i.e., an absence of amino or carboxyl groups) precluded the use of conventional coupling procedures, except possibly to the unusual "C-9-amino acid" in position 1(N-methyl-(4R)-4-butenyl-(L)-threonine) (15-17). However, modification of this amino acid was ill advised since this residue was critical to the biological activity of CyA. 10 CyC has threonine instead of  $\gamma$ -aminobutyric acid at the second amino acid position (AA2). This analog is biologically active and has been used to prepare cyclosporine-protein conjugates using the hemisuccinate derivative (15, 5). As noted by Kahan, however, coupling to this residue was likely to lead to steric interference with the "active" portion of the molecule (18). This conclusion was based on substitution studies in which it had been shown that amino acids 11, 1, 2, and 3 were critical for immunosuppressive activity (17). Because of this possibility, we used a photochemical procedure that has provided random links to the various exposed methyl or methylene groups of CyA. By having populations of CyA derivatives heterogeneous with regard to attachment sites, it was insured that a portion of the molecules could be coupled to protein without the active amino acids being buried. 25

30 We first reacted p-nitrophenyl-2-diazo-3,3,3-trifluoropropionate (19, 20) with a large excess of aminohexanoic acid in anhydrous dimethyl formamide. The reaction mixture was incubated in the dark at room temperature for 18 hours, following a similar procedure described by Samuels and coworkers (21). The product 35

-35-

was isolated by preparative TLC (21) and has the following formula:



5 Next CyA, which is very soluble in all organic solvents except hexane (17), was mixed with the above product in a benzene solvent and photolyzed. Two moles of carbene precursor to one mole cyclosporine A were also used. The mixture was irradiated with UV light from a mercury arc (mainly 254 nm). Reaction conditions were empirically chosen to avoid multiple substitutions of CyA molecules. Derivatized CyA (CyA-Hex) were separated by TLC. To provide a functional group that reacted with amino groups, the carboxyl group(s) of CyA-Hex were activated by conversion to the N-hydroxy succinimide (NHS) ester in the presence of dicyclohexylcarbodiimide. Then, CyA-Hex-NHS was dissolved in anhydrous dimethyl formamide and added as a small volume to bovine albumin and keyholelimpet hemocyanin in pH=8.8 bicarbonate buffer and incubated overnight at 4°C. These conditions have been found to work well with other NHS derivatives (22, 23). To determine the degree of substitution of protein amino acid groups by CyA-Hex, we used the trinitrobenzene sulfonic acid procedure of Habeeb (24). In our previous studies, BSA and KLH conjugates were both found to work well as immunogens and as antigens in solid phase immunoassays. All chemicals needed for the preparation of these reagents were commercially available.

30 To prepare a CyA affinity column, an excess of CyA-Hex-NHS in anhydrous dimethyl formamide was reacted with aminohexyl-Sepharose 4B (AH-Sepharose 4B®), suspended and swollen in the same solvent. This matrix, which

-36-

was prepared by a carbonyldiimidazole coupling procedure, avoided the introduction of the ion exchange groups associated with the frequently used cyanogen bromide coupling and reduced leakage due to the cross-linked agarose and the stable carbonyldiimidazole linkage (25). Trinitrobenzene sulfonic acid will be used to get a semiquantitative estimate of residual amino groups on Sepharose beads.

10

15

20

25

30

35

References

1. Borel, J.F. (1981) Cyclosporin-A - Present experimental status. Transplant Proc. 13, 344.
- 5 2. Borel, J.F. (Ed.) (1986) Cyclosporin-A: Progr. Allergy 38, 474 pp.
- 10 3. Beveridge, T. (1983) Cyclosporin-A: An evaluation of clinical results. Transplantation Proceed. 15, 433.
- 15 4. Shaw, L.M., Bowers, L., Demers, L., Freeman, D., Moyer, T., Sanghvi, A., Sellman, H. (1987) Critical Issues in Cyclosporine Monitoring: Report of the Task Force on Cyclosporine Monitoring. Clin. Chem. 33, 1269.
- 20 5. Donatsch, P., Abisch, E., Homberger, M., Traber, R., Trapp, M and Voges, R. (1981) A radioimmunoassay to measure cyclosporin A in plasma and serum samples. J. Immunoassay 2, 19.
- 25 6. Quesniaux, V.F.J., Tees, R., Schrier, M.H., Wenger, R.M., Donatsch, P. and Van Regenmortel, M.H.V. (1986) Monoclonal Antibodies to Cyclosporin. Prog. Allergy, 38, 108.
- 30 7. Bayley, H. (1983) In: T.S. Work and R.H. Burdon (Eds.) Laboratory Techniques in Biochemistry and Molecular Biology, Photogenerated Reagents in Biochemistry and Molecular Biology. Elsevier, Amsterdam p. 15.

-38-

8. Wenger, R.M. (1986) Progress in the Chemistry of Organic Natural Products, 50, 123.
- 5 9. Erlanger, A. (1980) The Preparation of Antigenic Hapten-Carrier Conjugates: A Survey. Methods in Enzymology, 70, 85.
- 10 10. Hestrin, S. (1949) The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine and its analytical application. J. Biol. Chem. 180, 249.
- 15 11. Cohen, W. and Erlanger, B.F. (1961) The presence of a second conformation - sensitive functional group at the active center of chymotrypsin. Biochem. Biophys. Acta 52, 604.
12. Sandoz Ltd. (1986) Insert of "Ciclosporin RIA-Kit," Fifth Edition, Basle, Switzerland.
- 20 13. Galardy, R.E., Craig, L.C. and Printz, M.P. (1973) Benzophenone triplet: A new photochemical probe of biological ligand-receptor interactions. Nature (London) New Biol. 242, 127.
- 25 14. Wenger, R.M. (1986) Cyclosporin and analogues: structural requirements of immunosuppressive activity. Transplant. Proc. 18, Suppl 5, 213.
- 30 15. Traber, T., Kuh, M., Rueegger, A., Lichti, H., Loosli, H.R., von Wartburg, A. (1977) Helvetia Chimica Acta, 59, 1480.
16. Wenger, R. (1983) Transplant Proc., Suppl 1, 2280.



-39-

17. Petcher, T.J., Weber, H.P., Rueegger, A. (1976)  
Helvetia Chimica Acta, 59, 1480.
18. Kahan, B.D. (1984) Am. J. Diseases, 3, 444.
- 5 19. Chowdhry, V., Vaughan, R., Westheimer, F.H. (1976)  
Proc. Natl. Acad. Sci. USA, 73, 1406.
- 10 20. Gupta, C.M., Radhakrishnan, R., Gerber, G.E.,  
Osen, W.L., Quay, S.C., Khorana, H.G. (1979) Proc.  
Natl. Acad. Sci. USA, 76, 2595.
21. Pascual, A., Casanova, J., Samuels, H.H. (1982) J.  
Biol. Chem., 257, 9640.
- 15 22. Guesdon, J.L., Ternynck, T., Avrameas, S. (1979)  
J. Histochem. Cytochem., 27, 1131.
- 20 23. Cleveland, W.L., Wood, I., Cone, R.E., Iverson,  
G.M., Rosenstein, R.W., Gershon, R.K., Erlanger,  
B.F. (1981) Proc. Natl. Acad. Sci. USA, 78, 7697.
24. Habee, A.F.S. (1966) Anal. Biochem., 14, 328.
- 25 25. Bethell, G.S., Ayers, J.S., Hancock, W.S., Hearn,  
M.T.W. (1979) J. Biol. Chem., 254, 2572.


30

35

-40-

What is claimed is:

1. A molecule having the structure:



wherein each R may independently be H or X, provided that at least one R is X, where X is a ligand which is produced as the result of a photochemical reaction between a precursor of X containing a photochemically activatable group and a hydrogen of cyclosporine A and which comprises a reactive group.

2. A molecule of claim 1, wherein the reactive group is a group which is reactive with a macromolecule.
3. A molecule of claim 2, wherein the macromolecule is a polypeptide.

-41-


4. A molecule of claim 3, wherein the polypeptide is a protein.

5. A molecule of claim 3, wherein the reactive group is a carboxyl group.

5


6. A molecule of claim 1, wherein X is

10




7. A molecule of claim 1, wherein X is

15




20

8. A molecule of claim 1, wherein X is



25

9. A molecule of claim 1, wherein X is



30

10. A molecule of claim 1, wherein the probability that only one R is X is greater than 0.75.

35

-42-

11. A molecule of claim 1, wherein the probability that only one R is X is about 1.0.
12. A molecule which comprises a congener of cyclosporine A characterized by the structural backbone of cyclosporine A in which one or more hydrogen atoms are replaced by one or more ligands, each such ligand:
- (a) being attached to the structural backbone of cyclosporine A at a location which a hydrogen atom has been replaced as the result of a photochemical reaction between a precursor of the ligand containing a photochemically activatable group and the hydrogen atom being replaced; and
- (b) comprising a reactive group.
13. An immunosuppressive composition useful for preventing organ rejection in a transplant subject comprising an amount of the molecules of claims 1, 3 and 12 effective to inhibit organ rejection in the transplant subject and a pharmaceutically acceptable carrier example of carrier.
14. A composition of matter which comprises a conjugate of a compound and the molecule of any of claims 1 or 12, wherein the compound is bound to the molecule through the reactive group of the ligand X.
15. A composition of matter which comprises a conjugate of a macromolecule and the molecule of claim 2, wherein the macromolecule is bound to the mole-

-43-

cule through the reactive group of the ligand X.

- 5 16. A composition of matter which comprises a conjugate of a polypeptide and the molecule of claim 3, wherein the polypeptide is bound to the molecule through the reactive group of the ligand X.
- 10 17. A composition of matter which comprises a conjugate of a protein and the molecule of claim 4, wherein the protein is bound to the molecule through the reactive group of the ligand X.
- 15 18. The composition of matter of claim 17, wherein the protein is bovine serum albumin.
- 20 19. The composition of matter of claim 17, wherein the protein is rabbit serum albumin.
- 20 20. The composition of matter of claim 17, wherein the protein is keyhole limpet hemocyanin.
- 25 21. The composition of matter of claim 17, wherein the protein is thyroglobulin.
- 25 22. The composition of matter of claim 17, wherein the protein is ovalbumin.
- 30 23. A method for preventing rejection in a transplant subject comprising administering to the subject an amount of the molecule of any of claims 1, 3 or 12 effective to inhibit organ rejection in the transplant subject.
- 35 24. An antibody directed to the composition of matter of claim 14 and specific for cyclosporine A or a

-44-

congener of cyclosporine A.

25. A polyclonal antibody of claim 24.

26. A monoclonal antibody of claim 24.

27. A detectably labeled antibody of any of claims 24, 25 or 26.

28. A method of detecting the presence of cyclosporine A or congener of cyclosporine A in a biological tissue sample which comprises treating the biological tissue sample with a detectably labeled antibody of claim 27 under conditions permitting the antibody to bind to cyclosporine A or congener and form a complex therewith, removing labeled antibody which is not bound to cyclosporine A or congener, detecting the presence of labeled antibody bound to cyclosporine A or congener and thereby detecting the presence of cyclosporine A or congener in the biological tissue sample.

29. A method of claim 28 wherein the biological tissue sample is kidney.

30. A method of detecting the presence of cyclosporine A or a congener of cyclosporine A in a biological tissue sample which comprises treating the biological tissue sample with an antibody of any of claims 24, 25 or 26 under conditions permitting the antibody to bind to cyclosporine A or congener and form a complex therewith, removing antibody which is not bound to cyclosporine A or congener, treating the complex with a labeled antibody directed to the unlabeled antibody under conditions

-45-

such that the labeled antibody binds to the unlabeled antibody of the complex, removing labeled antibody which is not bound to the complex, detecting the presence of labeled antibody bound to the complex and thereby detecting the presence of cyclosporine A or congener in the biological tissue sample.

31. A method of claim 30 wherein the biological tissue sample is kidney.

32. A method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample which comprises:

(a) contacting a solid support with an excess of the composition of matter of claim 14 under conditions permitting the composition of matter to attach to the surface of the solid support;

(b) contacting a predetermined volume of biological fluid sample with a predetermined amount of labeled antibody of claim 21 under conditions such that the cyclosporine A or congener in the sample binds to the labeled antibody and forms a complex therewith;

(c) contacting the resulting complex to the solid support to the surface of which the composition of matter is attached under conditions permitting the labeled antibody of the complex to bind to the composition of matter;

-46-

- 5 (d) treating the solid support so that only the composition of matter and labeled antibody of the complex bound thereto remain;
- (e) quantitatively determining the amount of labeled antibody of the complex bound to the composition of matter; and
- 10 (f) thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.
33. A method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample which comprises:
- 15 (a) contacting a solid support with an excess of the composition of matter of claim 14 under conditions permitting the composition of matter to attach to the surface of the solid support;
- 20 (b) contacting a predetermined volume of biological fluid sample with a predetermined amount of antibody of any of claims 24, 25 or 26 under conditions such that the cyclosporine A or congener in the sample binds to the antibody and forms a complex therewith;
- 25 (c) contacting this complex with a predetermined amount of labeled antibody directed to the unlabeled antibody under conditions such that the labeled antibody binds to the unlabeled antibody complex of step (b) and forms a labeled complex therewith;
- 30
- 35



-47-

- 5 (d) contacting the resulting labeled complex to the solid support to the surface of which the composition of matter is attached under conditions permitting the unlabeled antibody bound to the labeled antibody of the labeled complex to bind to the composition of matter;
- 10 (e) treating the solid support so that only the composition of matter and labeled complex bound thereto remain;
- 15 (f) quantitatively determining the amount of labeled antibody of the labeled complex bound to the unlabeled antibody which is in turn bound to the composition of matter; and
- 20 (g) thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.
34. A method of claims 32 and 33 wherein the composition of matter is attached to the surface of the plate by noncovalent bonds.
- 25 35. A method of claims 32 and 33 wherein the composition of matter is attached to the surface of the plate by covalent bonds.
- 30 36. A method of determining the concentration of cyclosporine A or congener of cyclosporine A in a biological fluid sample by radioimmunoassay which comprises:

-48-

- (a) radioactively labeling a predetermined amount of a substance comprising cyclosporine A, congener of cyclosporine A or the composition of matter of claim 14;
- 5 (b) adding the predetermined amount of radiolabeled substance to the biological fluid sample;
- 10 (c) contacting the mixture of (b) with a predetermined amount of antibody of any of claims 24, 25 or 26 under conditions suitable to permit the antibody to bind to the cyclosporine A or congener in the biological fluid sample and the labeled substance;
- 15 (d) removing any unbound radiolabeled substance;
- (e) quantitatively determining the amount of labeled substance bound to the antibody; and
- 20 (f) thereby determining the concentration of cyclosporine A or congener in the biological fluid sample.
- 25 37. A method of monitoring levels of cyclosporine A or congener of cyclosporine A in a subject which comprises:
- (a) taking biological fluid samples from a sub-
- 30 ject at predetermined intervals; and
- (b) determining the amount of cyclosporine A or congener in each biological fluid sample according to claims 32, 33 or 36.
- 35

-49-

38. A method of claims 32, 33, 36 or 37 wherein the biological fluid is blood.
- 5 39. A method of claims 32, 33, 36 or 37 wherein the biological fluid is urine.
40. A method of claims 32, 33, 36 or 37 wherein the biological fluid is feces.
- 10 41. A method of claims 32, 33, 36 or 37 wherein the biological fluid is extracts of tissue.
42. A method for producing a monoclonal auto-anti-idiotypic antibody which comprises:
- 15 (a) contacting lymphoid cells of an animal under suitable conditions with an effective antibody-raising amount of the composition of matter of claim 14;
- 20 (b) collecting the lymphoid cells at a suitable time after the contacting;
- 25 (c) fusing the collected lymphoid cells with appropriate myeloma cells to produce a series of hybridoma cells each of which produces a monoclonal antibody;
- 30 (d) screening under suitable conditions the series of hybridoma cells so produced to identify those which secrete a monoclonal antibody capable of binding to an antibody directed to the composition of matter of claim 14;

35

-50-

(e) separately culturing a hybridoma cell so identified in an appropriate medium; and

(f) separately recovering under suitable conditions the monoclonal anti-idiotypic antibody produced by the hybridoma cell.

- 5
43. An antibody directed to the monoclonal auto-anti-idiotypic antibody of claim 42.
- 10
44. An antibody directed to the antibody of claim 24.
45. An antibody directed to the antibody of claim 25.
- 15
46. An antibody directed to the antibody of claim 26.
- 20
47. An immunoregulatory substance useful for preventing organ rejection in a transplant subject comprising an amount of the antibodies of any of claims 43, 44, 45 and 46 effective to inhibit organ rejection in a transplant subject and a pharmaceutically acceptable carrier.
- 25
48. A method of reducing the amount of cyclosporine A or congener of cyclosporine A in a subject which comprises administering intravenously to the subject an amount of the antibody of claims 24, 25 or 26 or fragment thereof effective to reduce the amount of cyclosporine A or congener and permitting the antibody or fragment thereof to bind to
- 30
- the excess cyclosporine A or congener, thereby rendering the excess cyclosporine A or congener ineffective.

-51-


49. A method of reducing the amount of endogenous immunoregulatory substances, or other biologically active substances which are endogenous, which share epitopes with cyclosporine A or congener of cyclosporine A in a subject which comprises administering intravenously to the subject an amount of antibody of any of claims 43, 44, 45 or 46 or fragment thereof effective to reduce the amount of endogenous substances and permitting the antibody or fragment thereof to bind to the excess endogenous substances, thereby rendering the excess endogenous substances ineffective.

50. A method of testing the potential of a pharmacological agent as an immunoactive agent which comprises running an immunochemical assay competitive between the pharmacological agent and known amounts of labeled cyclosporine A or congener of cyclosporine A with the antibody of any of claims 24, 25 or 26 under conditions such that the antibody forms complexes with the pharmacological agent and cyclosporine A or congener and determining the displacement from the antibody of labeled cyclosporine A or congener by the pharmacological agent.

30


35


**FIGURE 1**  
**1/4**




$\text{RH} = \text{C}_5\text{A}$  (H = hydrogen of  $\text{C}_5\text{A}$  side chain)

**SUBSTITUTE SHEET**

**FIGURE 2**  
**2/4****SUBSTITUTE SHEET**

**FIGURE 3**  
**3/4****SUBSTITUTE SHEET**



**FIGURE 4**  
**4/4****SUBSTITUTE SHEET**

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/05484

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC (5) A61K 37/02; C07K 7/64		
US CL 514/11; 530/317		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
US CL	514/11 530/317	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	US, A, 4,681,754, (H. SIEGL) 21 July 1987	1-13, 23
A	US, A, 4,722,999, (R. E. HANDSCHUMACHER ET AL) 02 February 1988	1-13, 23
A,E	US, A, 4,914,188 (F. J. DUMONT ET AL) 03 April 1990	1-13, 23
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
02 MAY 1990	21 MAY 1990	
International Searching Authority	Signature of Authorized Officer	
ISA/US	CHRISTINE M. NUCKER	